213 related articles for article (PubMed ID: 34847904)
41. The usefulness of thyroid size and TSH receptor antibody (TRAb) determinations in predicting the effectiveness of tiamazole and I-131 treatment for Graves-Basedow's disease.
Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):242-7. PubMed ID: 15314993
[TBL] [Abstract][Full Text] [Related]
42. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
[TBL] [Abstract][Full Text] [Related]
43. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa.
McLachlan SM; Rapoport B
Thyroid; 2013 Jan; 23(1):14-24. PubMed ID: 23025526
[TBL] [Abstract][Full Text] [Related]
44. TSH-receptor antibodies determined by the first, second and third generation assays and thyroid-stimulating antibody in pregnant patients with Graves' disease.
Kamijo K
Endocr J; 2007 Aug; 54(4):619-24. PubMed ID: 17641440
[TBL] [Abstract][Full Text] [Related]
45. Preserved activation of thyrotropin receptor antibody to stimulate thyroid function despite long-term treatment in euthyroid patients with Graves' disease.
Akuzawa M; Murakami M; Yamada M; Satoh T; Shimizu H; Mori M
Eur J Endocrinol; 1998 Mar; 138(3):281-5. PubMed ID: 9539302
[TBL] [Abstract][Full Text] [Related]
46. Risk factors of hyperthyroidism with hepatic function injury: a 4-year retrospective study.
Li C; Tan J; Zhang G; Meng Z; Wang R; Li W; Zheng W
Horm Metab Res; 2015 Mar; 47(3):209-13. PubMed ID: 24867136
[TBL] [Abstract][Full Text] [Related]
47. Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy.
Ryder M; Wentworth M; Algeciras-Schimnich A; Morris JC; Garrity J; Sanders J; Young S; Sanders P; Furmaniak J; Rees Smith B
Thyroid; 2021 Oct; 31(10):1597-1602. PubMed ID: 34114495
[No Abstract] [Full Text] [Related]
48. Pretreatment with betamethasone of patients with Graves' disease given radioiodine therapy: thyroid autoantibody responses and outcome of therapy.
Gamstedt A; Karlsson A
J Clin Endocrinol Metab; 1991 Jul; 73(1):125-31. PubMed ID: 2045463
[TBL] [Abstract][Full Text] [Related]
49. Determination of the levels of anti-thyroid-stimulating hormone receptor antibody with thyroid peroxidase antibody in Omani patients with Graves' disease.
Alnaqdy A; Al-Maskari M
Med Princ Pract; 2005; 14(4):209-12. PubMed ID: 15961927
[TBL] [Abstract][Full Text] [Related]
50. Thyroid-stimulating antibody in a patient with euthyroid Graves' disease.
Kubo T; Toki J; Kado Y; Kurihara M; Moriwake T; Kanzaki S; Seino Y
Endocr J; 2000 Apr; 47(2):197-201. PubMed ID: 10943745
[TBL] [Abstract][Full Text] [Related]
51. The effect of thyrotropin-receptor blocking antibodies on stimulating autoantibodies from patients with Graves' disease.
Lenzner C; Morgenthaler NG
Thyroid; 2003 Dec; 13(12):1153-61. PubMed ID: 14751037
[TBL] [Abstract][Full Text] [Related]
52. Diagnostic testing for Graves' or non-Graves' hyperthyroidism: A comparison of two thyrotropin receptor antibody immunoassays with thyroid scintigraphy and ultrasonography.
Scappaticcio L; Trimboli P; Keller F; Imperiali M; Piccardo A; Giovanella L
Clin Endocrinol (Oxf); 2020 Feb; 92(2):169-178. PubMed ID: 31742747
[TBL] [Abstract][Full Text] [Related]
53. POSITIVE THYROTROPIN RECEPTOR ANTIBODIES IN PATIENTS WITH TRANSIENT THYROTOXICOSIS.
Angell TE; Van Benschoten O; Cohen DA; Haas AV; Alexander EK; Marqusee E
Endocr Pract; 2018 Jun; 24(6):512-516. PubMed ID: 29624097
[TBL] [Abstract][Full Text] [Related]
54. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
[TBL] [Abstract][Full Text] [Related]
55. Long-term immunological study in Graves' disease treated with thyroid arterial embolization.
Zhao W; Gao BL; Jin CZ; Yi GF; Yang HY; Li H; Song DP; Hu JH; Jiang YN
J Clin Immunol; 2008 Sep; 28(5):456-63. PubMed ID: 18633697
[TBL] [Abstract][Full Text] [Related]
56. Identification of Two Different Phenotypes of Patients with Amiodarone-Induced Thyrotoxicosis and Positive Thyrotropin Receptor Antibody Tests.
Cappellani D; De Marco G; Ferrarini E; Torregrossa L; Di Certo AM; Cosentino G; Urbani C; Marconcini G; Mattiello A; Manetti L; Agretti P; Basolo F; Tonacchera M; Bartalena L; Bogazzi F
Thyroid; 2021 Oct; 31(10):1463-1471. PubMed ID: 34271828
[No Abstract] [Full Text] [Related]
57. Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.
Sawicka-Gutaj N; Budny B; Zybek-Kocik A; Sowiński J; Ziemnicka K; Waligórska-Stachura J; Ruchała M
Endocrine; 2016 Aug; 53(2):497-504. PubMed ID: 26767650
[TBL] [Abstract][Full Text] [Related]
58. A case of pulmonary metastatic thyroid cancer complicated with Graves' disease.
Suzuki K; Nakagawa O; Aizawa Y
Endocr J; 2001 Apr; 48(2):175-9. PubMed ID: 11456264
[TBL] [Abstract][Full Text] [Related]
59. Consistency Between Thyrotropin Receptor Antibody (TRAb) and Thyroid-Stimulating Antibody (TSAb) Levels in Patients with Graves Disease.
Huang Y; Jin B; Huang Y; Dong A
Lab Med; 2022 Jul; 53(4):412-416. PubMed ID: 35285929
[TBL] [Abstract][Full Text] [Related]
60. Serum Thyroid Hormone Balance in Levothyroxine Monotherapy-Treated Patients with Atrophic Thyroid After Radioiodine Treatment for Graves' Disease.
Ito M; Kawasaki M; Danno H; Kohsaka K; Nakamura T; Hisakado M; Yoshioka W; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Nakamura H; Miyauchi A
Thyroid; 2019 Oct; 29(10):1364-1370. PubMed ID: 31411123
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
